Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Vibrating shoe aims to boost walking speed in Parkinson's patients

NCT ID NCT07308418

Symptom relief Sponsor: Magnes AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This small pilot study tests a smart shoe called NUSHU that provides gentle vibrations to see if it can help people with Parkinson's disease walk faster. Sixteen participants will complete two short walking tests—one with the vibration on and one without—to compare their speed, stride, and safety. The goal is to gather early evidence for future, larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

16 people

The number who actually took part.

Started

Jan 2026

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * A medically confirmed diagnosis of Parkinson's disease on the physiotherapy prescription. * Stable medication for at least four weeks (no change in dopaminergic therapy). * The ability to walk at least 200 metres without stopping. * Minimum age: 18 years * Sufficient knowledge of German to understand the study information and complete the questionnaires. * Written informed consent form Exclusion criteria: * Atypical or secondary Parkinsonism * Sensory disturbances in the feet (e.g. polyneuropathy). * Other neurological, orthopaedic or internal medical conditions that significantly affect walking * Cognitive impairments that interfere with understanding the study information or following instructions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson's disease (PD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson's disease (PD)

Contacts and locations

Locations

  • Magnes AG

    Zurich, Canton of Zurich, 8005, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.